GE Healthcare has integrated Medtronic Microstream capnography (CO2) and INVOS regional oximetry (rSO2) technology into its Carescape precision monitoring platform for perioperative and ICU care.

FDA clearance and CE Mark approval of the integration of these latest technologies on the Carescape platform completes the full suite of Medtronic patient monitoring technologies available on the system. The combined solution also features GE Healthcare FlexAcuity which gives clinicians around the world the ability to choose care options based on patient acuity needs and assist them in their goal of earlier detection of patient deterioration.

“Our longstanding collaboration with Medtronic allows GE Healthcare to integrate clinically advanced parameters to enable clinicians with precision monitoring for individualized care,” said Neal Sandy, general manager for Monitoring Solutions at GE Healthcare. “We are able to add these capabilities to both new and existing enterprise monitoring systems, ensuring clinicians have access to real-time, reliable patient insights that can play a critical role in care decisions and outcomes.”

Since before the inception of the Carescape platform, Medtronic solutions have been integrated into GE Healthcare technologies for comprehensive patient monitoring.  This partnership with Medtronic helps enable GE Healthcare’s vision to connect caregivers and their patients within an ecosystem that aims to support patient care, enable better decision making, and drive efficiencies for healthcare systems.

“Personalizing care to each patient is the standard of care. As providers, we prioritize how care is given based on individual patient acuity, so, when we’re working with a monitoring platform, it is helpful to be able to choose from different parameters to aid in capturing signs of deterioration as quickly as possible,” said Dr. Eva Masso Lago, MD, PhD, anesthesiologist with Germans Trias I. Pujol Hospital in Barcelona, Spain, who utilizes both Carescape and Medtronic INVOS monitors to care for cardiac surgery patients. “Bringing the new INVOS technology into the Carescape platform will add ergonomic benefits, enhance ease of use and improve workflow.”

The INVOS regional oximetry (rSO2) technology solution monitors for signs of hemodynamic changes and deteriorating patient conditions associated with cerebral desaturation events. When used as an indication of compromised cerebral oxygenation, INVOS technology can help clinicians return the patient’s rSO2 to baseline and has been shown to improve postoperative outcomes including hospital length of stay, POD, and MOMM. Patients undergoing on-pump coronary artery bypass grafting (CABG) spent an average of 14 hours less in the ICU when receiving near-infrared spectroscopy-guided care with INVOS rSO2.

The advanced Microstream™ capnography (CO2) technology solution offers clinicians early indication of patient decline[i] and is validated for neonate to adult patients. It uses a proprietary CO2-specific infrared wavelength that is highly accurate and unaffected by the presence of other gases. The technology also features Smart Capnography algorithms engineered to enhance patient safety, improve clinical workflow, and ease alarm fatigue by reducing clinically insignificant nuisance alarms by 53%.  This technology potentially cuts down on the high demand placed on providers to respond to non-emergent issues.

“Medtronic and GE Healthcare are both committed to expanding access to patient care around the world,” said Frank Chan, president of the Patient Monitoring business, which is part of the Medical Surgical Portfolio at Medtronic. “This collaboration brings together our combined medical technology leadership to improve workflow, allowing clinicians more time to focus on what matters most – the patient. Together, we are empowering clinicians with actionable insights to personalize care.”

GE Healthcare and Medtronic have received CE (Conformité Européenne) Mark on the technologies included in this advanced system as well as U.S. Food and Drug Administration (FDA) 510(k) clearance for Carescape software v3.2 with Microstream and INVOS.

The Microstream capnography and INVOS monitoring systems should not be used as the sole basis for diagnosis or therapy and are intended only as adjunct in patient assessment.